characteristics.text: 2025-01-31
characteristics.characteristic: ENA first public
characteristics.text: ERC000011
characteristics.characteristic: ENA-CHECKLIST
characteristics.text: Department of Physiology and Pharmacology Karolinska Institutet
characteristics.characteristic: INSDC center name
characteristics.text: public
characteristics.characteristic: INSDC status
characteristics.text: ERS22587724
characteristics.characteristic: SRA accession
characteristics.text: E-MTAB-14701:Sample 7
characteristics.characteristic: Submitter Id
characteristics.text: ArrayExpress
characteristics.characteristic: broker name
characteristics.text: cancer cell line
characteristics.characteristic: cell_type
characteristics.text: not collected
characteristics.characteristic: collection date
characteristics.text: human
characteristics.characteristic: common name
characteristics.text: Protocols: GSK-615 or DMSO were used to treat ES2, SUM159, and A549 cells. For ES2 and A549, the cells were collected after 8 and 16 hours, and for SUM159, after 24 hours.  As directed by the manufacturer, total RNA was extracted using the PureLinkTM RNA Mini Kit. All samples were treated with DNase using the PureLinkTM DNase Set.  Illumina TruSeq Stranded mRNA library preparation using RNA as input and Poly-A selection.
characteristics.characteristic: description
characteristics.text: not collected
characteristics.characteristic: geographic location (country and/or sea)
characteristics.text: not applicable
characteristics.characteristic: isolate
characteristics.text: Homo sapiens
characteristics.characteristic: organism
characteristics.text: Homo sapiens
characteristics.characteristic: organism
characteristics.text: Homo sapiens
characteristics.characteristic: scientific_name
characteristics.text: Sample 7
characteristics.characteristic: title